An article titled “EHA: Dasatinib gets early edge over imatinib in CML,” published June 14, 2015, misstated the type of cancer treated in the study. The dasatinib/imatinib SPIRIT2 trial is in chronic myeloid leukemia.
An article titled “EHA: Dasatinib gets early edge over imatinib in CML,” published June 14, 2015, misstated the type of cancer treated in the study. The dasatinib/imatinib SPIRIT2 trial is in chronic myeloid leukemia.
FROM PEDIATRICS A 3- to 6-month learning program for pediatric and family medicine providers ...
FROM JAMA SURGERY Frailty was associated with a significant increase in 30-day complications after ...
Influenza vaccine needs some help with its image. I suspect most health care providers ...
